Wild-type (senile) amyloidosis MRI

Wild-type (senile) amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) amyloidosis MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) amyloidosis MRI
CDC on Wild-type (senile) amyloidosis MRI
Wild-type (senile) amyloidosis MRI in the news
Blogs on Wild-type (senile) amyloidosis MRI
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) amyloidosis MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

MRI

Cardiovascular Magnetic Resonance (CMR)

• T1 sequence of CMR with the use of gadolinium can differentiate extracellular tissue thickening due to myocardial hypertrophy vs. extracellular deposition.
• Using pre- and post-contrast T1 mapping, extracellular volume (ECV) can be calculated, which is a direct measurement of the cardiac interstitium.
• ECV expansion is a quantitative marker of the amyloid burden and can detect amyloid fibrils infiltration earlier than conventional testing.